Evolent Health (NYSE:EVH) was downgraded by research analysts at JPMorgan Chase to a “hold” rating in a note issued to investors on Tuesday. They presently have a $17.00 price target on the technology company’s stock. JPMorgan Chase’s price target suggests a potential upside of 2.10% from the stock’s current price. Several other equities research analysts […]
